| Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
| Aptamer Group Plc |
LSE:APTA |
London |
Ordinary Share |
GB00BNRRP542 |
ORD 0.1P |
| |
Price Change |
% Change |
Share Price |
Shares Traded |
Last Trade |
| |
0.00 |
0.0% |
96.00 |
0.00 |
08:00:00 |
| Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
|
92.00
|
100.00
|
96.00 |
96.00 |
96.00 |
| Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
|
Health Care Equipment & Services
|
|
|
|
|
66
|
| Last Trade Time |
Trade Type |
Trade Size |
Trade Price |
Currency |
| - |
O |
0 |
96.00 |
GBX |
| Trade Time |
Trade Price |
Trade Size |
Trade Value |
Trade Type |
No Trades
| Date | Subject |
|---|
03/7/2022
09:20 | Aptamer Daily Update: Aptamer Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 96p.
Aptamer Group Plc has a 4 week average price of 96p and a 12 week average price of 96p.
The 1 year high share price is 153p while the 1 year low share price is currently 96p.
There are currently 69,012,594 shares in issue and the average daily traded volume is 1,175 shares. The market capitalisation of Aptamer Group Plc is £66,252,090.24.
|
24/2/2022
06:52 | timbo003: Liberum have issued an initiation note this morning
https://www.research-tree.com/companies/uk/health/aptamer-group-plc/APTA/LON
Summary:
The affinity ligand market is large (~$145bn) and growing at
double digits. It is dominated by antibody technology, but
they aren’t perfect, falling short of requirements 50% of the
time. Aptamer has developed an alternate affinity ligand
technology that has proven effective in 70% of projects
where antibodies have failed. Aptamer’s fee-for-service
model is gaining traction with healthcare partners across a
range of applications, and the BD pipeline has grown
accordingly. Our DCF model values Aptamer at £185m, or
£2.70 per share, 105% upside. We initiate with a BUY.
|
24/1/2022
10:54 | amanitaangelicus: Still holding small amount. No interest in the stock. Will take time. Sell price set from the outset.
|
17/1/2022
13:51 | elpirata: Yes, already contracted with big pharma & should see revenue increases compounding year on year.
But its the wrong price for me to buy in at this level, £98m mcap for a company that reported a £2.9m loss on £1.6m revenues for the 15 month period to 30/6/21 is too hot imo. They need £3m pa just to cover staff & director costs.
Keeping it on monitor.
|
Aptamer share price data is direct from the London Stock Exchange
PLUS1
Aptamer appoints Fulcrum's Jenny Cutler as interim CFO